Search
Tirapazamine
go.drugbank.com/drugs/DB04858InvestigationalTirapazamine entered phase III testing in 2006 for patients with head and neck cancer and gynecological cancer, as well as for other solid tumor cancer types. … For all these reasons, the combination of tirapazamine with other anticancer treatments is highly recommended.
Cyclothiazide
go.drugbank.com/drugs/DB00606ApprovedAs a diuretic, cyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like cyclothiazide also inhibi...
NP2
go.drugbank.com/drugs/DB06308InvestigationalIt was under investigation in clinical trial NCT01291901 (NP2 Enkephalin For Treatment of Intractable Cancer Pain).
Rubidium Rb-82
go.drugbank.com/drugs/DB09479ApprovedInvestigationalIt is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected
Zanamivir
go.drugbank.com/drugs/DB00558ApprovedInvestigationalA guanido-neuraminic acid that is used to inhibit neuraminidase.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseErtiprotafib
go.drugbank.com/drugs/DB06521ExperimentalErtiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes.
Betazole
go.drugbank.com/drugs/DB00272ApprovedA histamine H2 agonist used clinically to test gastric secretory function.
Categories: Tests for Gastric SecretionBelzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigationalBelzutifan received FDA approval for the treatment of select VHL-associated cancers on August 13, 2021. … [L36105] Initially considered to be undruggable, a binding pocket was eventually discovered in the HIF-2α molecule which allowed for compounds to bind and inhibit these proteins.
Chloropyramine
go.drugbank.com/drugs/DB08800InvestigationalIt is also indicated for Quincke's edema, allergic reactions to insect bites, food and drug allergies, and anaphylactic shock.
Categories: Antihistamines for Systemic Use, Antihistamines for Topical UseTelisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigationalto be approved for this specific patient population. … [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment